# Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

> **NCT01076192** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 547 (actual)

## Conditions studied

- Moderate-to-severe Chronic Plaque Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01076192
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2016-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076192, "Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01076192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*